Zimbabwe Changes Course and Accepts Use of Ivermectin for Research as a Care Option

Zimbabwe Changes Course and Accepts Use of Ivermectin for Research as a Care Option

With growing numbers of SARS-CoV-2 cases in the southeastern African nation of Zimbabwe, once known as "the Jewel of Africa," TrialSite recently shared the entire nation was ramping up its defenses and that now includes the proactive use of Ivermectin for research purposes. That nation’s Health recently communicated to the Medicines Control Authority of Zimbabwe (MCAZ) that, “In these difficult times of COVID-19 treatment, we have to be careful to protect patients as well as not to deny them effective treatment regimens.” The ministry went on, “It is in this regard, the authority is hereby granted for you to proceed to allow importation and use of these medicines under the supervision and guidance you outlined. Ivermectin can be evaluated for both treatment and prophylaxis.” This government decree, provisional and under emergency conditions, was the result of a major spike in the number of cases and deaths in the country. With growing word of the drug’s potential efficacy, exemplified in what is now over two dozen clinical trials from multiple primarily low to middle-income countries (LMICs) the authorities here also sought to stop illicit use of the variety of the drug meant for ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee